Open AccessEffects of ranibizumab on human corneal endothelial cells
Author(s) -
Yi-Jung Ho,
Yi–Yu Tsai,
Jane-Ming Lin,
WenLu Chen,
Chun-Ju Lin,
Chun-Yi Chiang
Publication year - 2014
Publication title -
taiwan journal of ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.519
H-Index - 9
eISSN - 2211-5072
pISSN - 2211-5056
DOI - 10.1016/j.tjo.2014.04.004
Subject(s) - ranibizumab , medicine , ophthalmology , macular degeneration , surgery , bevacizumab , chemotherapy
PurposeThis study aims to evaluate corneal endothelial changes occurring over a 3-month period after intravitreal injections of ranibizumab in patients with wet age-related macular degeneration.MethodsThis is a prospective case series. A total of 29 patients (29 eyes) received a 0.5-mg intravitreal injection of ranibizumab. Specular microscopy, including measurement of central corneal thickness and endothelial cell count, was performed on each patient prior to and after completing three intravitreal injections.ResultsAll patients received three intravitreal injections and were followed up for a mean of 3 months. There was no significant change in corneal thickness (p = 0.32) or endothelial cell density (p = 0.38) after ranibizumab injections.ConclusionIntravitreal ranibizumab injections (0.5 mg) have no harmful effects on corneal endothelial cells